Intravenous physostigmine increases cerebrospinal fluid neuropeptide-Y

Wade H. Berrettini, Nancy A. Garrick, John Nurnberger, Susan Simmons-Alling, Joel Gelernter, Phillip W. Gold, David R. Rubinow, Dennis L. Murphy

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The ability to measure directly central nervous system (CNS) neurotransmitter changes after an acute pharmacological challenge would be a useful clinical tool in psychiatric research. As one approach to this possibility, we attempted to measure cerebrospinal fluid (CSF) neuropeptide changes produced by an intravenous infusion of the indirect cholinergic agonist physostigmine. Six rhesus monkeys, with indwelling CSF catheters, had serial CSF samples removed before and after a 15 μg/kg physostigmine infusion. Five of six monkeys studied showed at least a 50% increase in CSF neuropeptide-Y (NPY) levels. Normal human subjects (n = 27) had CSF sampled before and 15, 30, and 45 min after an acute intravenous infusion of physostigmine (either 0, 5, or 15 μg/kg). An Analysis of Variance revealed a significant (p = 0.04) dose-time interaction, suggesting that physostigmine increased CSF NPY at the 15 μg/kg dose. CSF levels of seven other neuropeptides remained unchanged. These results suggest that the pharmacological challenge paradigm can be adapted to CSF neuropeptides, providing new measures of CNS stimulus-induced response beyond the peripheral plasma determinations usually employed.

Original languageEnglish
Pages (from-to)623-630
Number of pages8
JournalBiological Psychiatry
Volume26
Issue number6
DOIs
StatePublished - 1989

Fingerprint

Physostigmine
Neuropeptide Y
Cerebrospinal Fluid
Neuropeptides
Intravenous Infusions
Central Nervous System
Pharmacology
Cholinergic Agonists
Macaca mulatta
Haplorhini
Neurotransmitter Agents
Psychiatry
Analysis of Variance
Catheters

ASJC Scopus subject areas

  • Biological Psychiatry

Cite this

Berrettini, W. H., Garrick, N. A., Nurnberger, J., Simmons-Alling, S., Gelernter, J., Gold, P. W., ... Murphy, D. L. (1989). Intravenous physostigmine increases cerebrospinal fluid neuropeptide-Y. Biological Psychiatry, 26(6), 623-630. https://doi.org/10.1016/0006-3223(89)90087-5

Intravenous physostigmine increases cerebrospinal fluid neuropeptide-Y. / Berrettini, Wade H.; Garrick, Nancy A.; Nurnberger, John; Simmons-Alling, Susan; Gelernter, Joel; Gold, Phillip W.; Rubinow, David R.; Murphy, Dennis L.

In: Biological Psychiatry, Vol. 26, No. 6, 1989, p. 623-630.

Research output: Contribution to journalArticle

Berrettini, WH, Garrick, NA, Nurnberger, J, Simmons-Alling, S, Gelernter, J, Gold, PW, Rubinow, DR & Murphy, DL 1989, 'Intravenous physostigmine increases cerebrospinal fluid neuropeptide-Y', Biological Psychiatry, vol. 26, no. 6, pp. 623-630. https://doi.org/10.1016/0006-3223(89)90087-5
Berrettini, Wade H. ; Garrick, Nancy A. ; Nurnberger, John ; Simmons-Alling, Susan ; Gelernter, Joel ; Gold, Phillip W. ; Rubinow, David R. ; Murphy, Dennis L. / Intravenous physostigmine increases cerebrospinal fluid neuropeptide-Y. In: Biological Psychiatry. 1989 ; Vol. 26, No. 6. pp. 623-630.
@article{07efc50d9bee4b13acc4f4ae667f1dd2,
title = "Intravenous physostigmine increases cerebrospinal fluid neuropeptide-Y",
abstract = "The ability to measure directly central nervous system (CNS) neurotransmitter changes after an acute pharmacological challenge would be a useful clinical tool in psychiatric research. As one approach to this possibility, we attempted to measure cerebrospinal fluid (CSF) neuropeptide changes produced by an intravenous infusion of the indirect cholinergic agonist physostigmine. Six rhesus monkeys, with indwelling CSF catheters, had serial CSF samples removed before and after a 15 μg/kg physostigmine infusion. Five of six monkeys studied showed at least a 50{\%} increase in CSF neuropeptide-Y (NPY) levels. Normal human subjects (n = 27) had CSF sampled before and 15, 30, and 45 min after an acute intravenous infusion of physostigmine (either 0, 5, or 15 μg/kg). An Analysis of Variance revealed a significant (p = 0.04) dose-time interaction, suggesting that physostigmine increased CSF NPY at the 15 μg/kg dose. CSF levels of seven other neuropeptides remained unchanged. These results suggest that the pharmacological challenge paradigm can be adapted to CSF neuropeptides, providing new measures of CNS stimulus-induced response beyond the peripheral plasma determinations usually employed.",
author = "Berrettini, {Wade H.} and Garrick, {Nancy A.} and John Nurnberger and Susan Simmons-Alling and Joel Gelernter and Gold, {Phillip W.} and Rubinow, {David R.} and Murphy, {Dennis L.}",
year = "1989",
doi = "10.1016/0006-3223(89)90087-5",
language = "English",
volume = "26",
pages = "623--630",
journal = "Biological Psychiatry",
issn = "0006-3223",
publisher = "Elsevier USA",
number = "6",

}

TY - JOUR

T1 - Intravenous physostigmine increases cerebrospinal fluid neuropeptide-Y

AU - Berrettini, Wade H.

AU - Garrick, Nancy A.

AU - Nurnberger, John

AU - Simmons-Alling, Susan

AU - Gelernter, Joel

AU - Gold, Phillip W.

AU - Rubinow, David R.

AU - Murphy, Dennis L.

PY - 1989

Y1 - 1989

N2 - The ability to measure directly central nervous system (CNS) neurotransmitter changes after an acute pharmacological challenge would be a useful clinical tool in psychiatric research. As one approach to this possibility, we attempted to measure cerebrospinal fluid (CSF) neuropeptide changes produced by an intravenous infusion of the indirect cholinergic agonist physostigmine. Six rhesus monkeys, with indwelling CSF catheters, had serial CSF samples removed before and after a 15 μg/kg physostigmine infusion. Five of six monkeys studied showed at least a 50% increase in CSF neuropeptide-Y (NPY) levels. Normal human subjects (n = 27) had CSF sampled before and 15, 30, and 45 min after an acute intravenous infusion of physostigmine (either 0, 5, or 15 μg/kg). An Analysis of Variance revealed a significant (p = 0.04) dose-time interaction, suggesting that physostigmine increased CSF NPY at the 15 μg/kg dose. CSF levels of seven other neuropeptides remained unchanged. These results suggest that the pharmacological challenge paradigm can be adapted to CSF neuropeptides, providing new measures of CNS stimulus-induced response beyond the peripheral plasma determinations usually employed.

AB - The ability to measure directly central nervous system (CNS) neurotransmitter changes after an acute pharmacological challenge would be a useful clinical tool in psychiatric research. As one approach to this possibility, we attempted to measure cerebrospinal fluid (CSF) neuropeptide changes produced by an intravenous infusion of the indirect cholinergic agonist physostigmine. Six rhesus monkeys, with indwelling CSF catheters, had serial CSF samples removed before and after a 15 μg/kg physostigmine infusion. Five of six monkeys studied showed at least a 50% increase in CSF neuropeptide-Y (NPY) levels. Normal human subjects (n = 27) had CSF sampled before and 15, 30, and 45 min after an acute intravenous infusion of physostigmine (either 0, 5, or 15 μg/kg). An Analysis of Variance revealed a significant (p = 0.04) dose-time interaction, suggesting that physostigmine increased CSF NPY at the 15 μg/kg dose. CSF levels of seven other neuropeptides remained unchanged. These results suggest that the pharmacological challenge paradigm can be adapted to CSF neuropeptides, providing new measures of CNS stimulus-induced response beyond the peripheral plasma determinations usually employed.

UR - http://www.scopus.com/inward/record.url?scp=0024325757&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024325757&partnerID=8YFLogxK

U2 - 10.1016/0006-3223(89)90087-5

DO - 10.1016/0006-3223(89)90087-5

M3 - Article

C2 - 2790099

AN - SCOPUS:0024325757

VL - 26

SP - 623

EP - 630

JO - Biological Psychiatry

JF - Biological Psychiatry

SN - 0006-3223

IS - 6

ER -